Compare Alexandria Real Estate Equities Inc (ARE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Alexandria Real Estate Equities Inc trades at $48.14 (market cap $8.28B), while State Street SPDR S&P Biotech ETF trades at $159.97. The key difference: Alexandria Real Estate Equities Inc pays a 5.99% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Alexandria Real Estate Equities Inc nearer its low. Which is the better fit depends on your goals.
| ARE | XBI | |
|---|---|---|
Market Cap | $8.28B | — |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $87.45 | $164.28 |
52-Week Low | $40.41 | $86.92 |
Enterprise Value | $20.98B | — |
Dividend Yield | 5.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alexandria Real Estate Equities (ARE) trades at $48.35, down 2.79% today, with a bearish technical signal and mixed fundamentals. The stock shows a negative net income margin of -37.12% for 2025, though recent Q2 2026 FFO beat estimates. Analyst consensus is a 'Buy' with a $53.71 price target, but technical indicators suggest near-term pressure with support at $47 and resistance at $50.
Outlook remains cautious due to profitability challenges and high debt, but leasing momentum and strategic partnerships offer recovery potential. Risks include ongoing net losses and market volatility, while institutional interest and dividend payments provide some stability. Investors should weigh fundamental weaknesses against long-term real estate sector recovery prospects.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
